Introduction
Hematopoiesis is the developmental process whereby hematopoietic stem cells (HSC) undergo proliferation to self renew and/or differentiate into more committed progenitor cells that generate mature blood cells. These progenitors have been purified and include hematopoietic stem cells (HSC), which give rise to more restricted common lymphoid progenitors (CLP) that differentiate into lymphoid cells, and common myeloid progenitors (CMP) that differentiate into more committed progenitors including the granulocyte-macrophage progenitor (GMP) and megakaryocyte-erythrocyte progenitor (MEP) to give rise to non-lymphoid cells. 1, 2 Several lines of evidence indicate that cell fate determination during hematopoietic development is dependent on the level of transcription factor expression. For example, the levels of E2A are critical for B or T cell fate determination 3, 4 , and the levels of PU.1 determine B cell or myeloid development 5, 6 . In addition, it has been proposed that HSC express low levels of transcriptional programs for many cell lineages, and that cell fate is determined by up-regulation of transcription factors that promote the differentiation of specific cell lineages, and the concomitant down-regulation of transcriptional regulators required for the development of other cell lineages. 7 For example, CCAAT enhancer binding protein α (C/EBPα) and PU.1 are expressed in HSC and are up-regulated in GMP during granulocyte, macrophage development, however, they are down regulated in MEP. 8, 9 In comparison, GATA-1 and FOG-1, which are required for erythroid differentiation, are up-regulated in MEP but not GMP or CLP. [8] [9] [10] Furthermore, inappropriate expression of transcription factors can reverse cell fate. For instance,
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11,12
C/EBPα is a basic leucine zipper transcription factor, which can positively or negatively affect gene transcription depending on the specific promoter or enhancer element that it binds. 13, 14 In this regard, C/EBPα regulates the expression of a number of genes involved in cell growth and differentiation, and has pivotal roles in lineage commitment in the hematopoietic system [15] [16] [17] [18] . For example, over-expression of C/EBPα in hematopoietic progenitor cell (HPC) lines induces granulocyte differentiation. In addition, C/EBPα also promotes neutrophil maturation at the expense of macrophage differentiation in U937 cells and in PU.1 -/-cell lines, indicating that C/EBPα may play a role in cell fate decisions in GMP. 6, 19, 20 C/EBPα is also a potent inhibitor of cell proliferation, and is thought to play a critical role in regulating the balance between proliferation, growth arrest and differentiation in GMP. [21] [22] [23] However, C/EBPα mRNA is also expressed in HSC and CMP, and C/EBPα is required for CMP to differentiate into GMP, suggesting that C/EBPα might regulate the proliferation and differentiation of progenitors more primitive than GMP. 1, 8, 24, 25 Furthermore, the expression of oncogenic BCR-ABL protein in normal hematopoietic progenitors decreases C/EBPα expression and promotes erythropoiesis, suggesting that C/EBPα may affect CMP differentiation. 26, 27 Based on these observations, we proposed that C/EBPα regulates cell fate decisions in progenitors more primitive than GMP, where it may influence the commitment to myeloid or erythroid differentiation.
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In the present report, we demonstrate that C/EBPα inhibits the differentiation and development of erythroid cells while promoting myeloid development. Moreover, C/EBPα induces myeloid differentiation of erythroid restricted progenitor cells.
Altogether, our data show C/EBPα affects hematopoietic cell fate decisions in two ways:
by inducing myeloid differentiation and inhibiting erythroid differentiation in progenitors more primitive than GMP.
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Materials and methods

Mice
The C/EBPα +/-mice (mixed background of 129sv and C57Bl/6) were backcrossed onto a pure C57Bl/6 background (Ly5.1). 28 Mice and embryos were genotyped by PCR of genomic DNA. Four to 8 week old C57Bl/6-Ly 5.2 mice were obtained for transplantation experiments from the animal production area at NCI-Frederick (Frederick, MD). Animal care was provided in accordance with the procedures outline in the "Guide for Care and Use of Laboratory Animals" (National Institute of Health, Bethesda, MD, 1996).
Soft Agar Colony Assays
To measure erythroid progenitors, FL from C/EBPα -/-, C/EBPα +/-and C/EBPα +/+ mice or FACS sorted cells were plated in 35 mm Lux petri dishes (Miles Laboratories, Inc.) at the indicated cell densities in Iscoves Modified Dulbecco's Medium (IMDM). Dishes were incubated in a fully humidified atmosphere at 37°C, 5% CO 2 and then scored for colony formation after 7-10 days.
Retroviral Transduction, FACS analysis, and Transplantation
Recombinant mouse stem cell virus (MSCV) vectors expressing C/EBPα and green fluorescent protein (GFP) were generated as previously described. 29 pMSCV-GFP and pMSCV-C/EBPα-GFP were transfected into Phoenix packaging cells (a gift from Dr.
Gary Nolan, Stanford University) with pCL-eco plasmids by Fugene 6 (Roche Applied obtained from all mice within a group, and then statistical differences between the groups were determined by the Student's t-test. All lineage specific antibodies and Tri-color streptavidin were purchased from BD Pharmingen. Gr-1, and TER119 were PEconjugated-antibodies, while Mac-1 and CD71 were biotin-conjugated antibodies.
Cell Lines
The mouse erythroleukemia (MEL) cell line was maintained in complete Dulbecco modified Eagle medium (cDMEM) without phenol red with 10% FCS, P/S/G. MEL cells that express conditionally active C/EBPα were established by infecting MEL cells with retroviral vectors that express C/EBPα/hER, or the control construct lacking C/EBPα/hER coding regions. C/EBPα/hER-infected MEL cells were cloned by limiting dilution in the presence of 2.0 μg/mL puromycin. The expression of C/EBPα was monitored by Western blot using anti-C/EBPα antibody (SC-61; Santa Cruz Biotechnology). MEL cells were seeded at 4 × 10 5 /mL in cDMEM containing 3mM hexamethylene bisacetamide (HMBA) and incubated at 37°C. Cells were stained for
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Western Blot Analysis
Cell lysates were resolved on gradient SDS-PAGE gels (Invitrogen) and transferred to Immobilon-P membrane (Millipore). The membrane was blocked at room temperature in 5% milk/Tris Buffered Saline-Tween (TBS-T) solution, and then probed with anti-rabbit C/EBPα antibody, anti-rat GATA-1 antibody (sc-265), anti-rabbit EpoR antibody (sc-697), anti-mouse α-actin antibody (sc-8432), anti-rabbit Id1 (sc-488), anti-rabbit PU.1 antibody (sc-352; Santa Cruz Biotechnology). All primary antibodies were diluted to 1:200. Bound antibody was detected using a chemiluminescence system (Amersham Biosciences UK Limited).
RT-PCR
Total RNA was purified using RNeasy (Qiagen) and converted to cDNA with Moloney murine leukemia virus reverse transcriptase (Applied Biosystems). The PCR was conducted using ampli-Taq DNA polymerase (PerkinElmer) at four different sets with different cycle numbers to confirm that the reaction was in the exponential phase. PCR amplification cycles consisted of 30 seconds at 94°C, 30 seconds at 58°C, and 1 minute at 72°C as indicated cycles. The primers used are as follows: 
Northern Blot Analysis
Total RNA was purified using RNeasy (Qiagen) as outlined by the manufacturer.
Separation of RNA samples (10 μg) by electrophoresis was performed on 1% agarose, 5.2% formaldehyde (37% solution), 1 × MOPS gels. The running buffer was 1 × MOPS, 5% formaldehyde. RNA was transferred to nylon membrane (MSI), and hybridized at 68ºC in QuickHyb® hybridization solution (Stratagene). Murine EpoR and β-globin cDNA probes were labeled with the random priming Prime-It® II kit (Stratagene) following the manufacturer's instructions. 
Construction of Luciferase Reporter Plasmids and Reporter Assay
C/EBPα inhibits erythroid differentiation of MEL Cells
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C/EBPα induces lineage switching of MEL, EML cells and normal MEP to the myeloid lineage
Since it was previously shown that C/EBPα reprograms B cell precursors to macrophages 12 , we determined if C/EBPα might act as a molecular switch to inhibit erythroid differentiation and promote myeloid development in committed erythroid progenitor cells that were transduced with pMSCV-GFP and pMSCV-C/EBPα-GFP. First, we examined if C/EBPα could promote myeloid development in erythroid committed MEL cells. We performed flow cytometry analysis with erythroid specific cell surface marker proteins, Taken together, these data suggest that C/EBPα can switch the lineage differentiation potential of committed erythroid progenitors to myeloid lineage.
C/EBPα inhibits erythropoietin receptor expression in differentiating MEL cells and fetal liver cells
To determine the molecular mechanisms by which C/EBPα regulates erythroid differentiation, we examined the expression of transcription factors that promote erythroid differentiation including GATA- The zinc finger transcription factor GATA-1 is required for erythroid development.
PU.1 is a known antagonist of GATA-1 function and can block erythroid differentiation, including the differentiation of MEL cells. 9, 10 Thus, it has been proposed that expression 14, 48 We have found that C/EBPα -/-FL HPC show increased cell proliferation and a block in the ability of CMP to differentiate to GMP. 24 Mutations in at least one allele of the C/EBPα gene, which result in loss of normal C/EBPα function, are present in 10% of from chronic phase to blast phase crisis is associated with down regulation of C/EBPα by the BCR-ABL fusion protein. 27 Thus, drugs that increase C/EBPα expression levels could not only be used to treat AML 52 , but also to treat chronic myeloproliferative diseases such as PV or CML, thereby, expanding the utility of C/EBPα as a potential therapeutic target.
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